@Article{096504016X14743324568129,
AUTHOR = {Xingtao Han, Jinjian Yang, Zhankui Jia, Pengtao Wei, Han Zhang, Wenwei Lv, Jiantao Sun, Qingxiang Huo},
TITLE = {Knockdown of Serine–Arginine Protein Kinase 1 Inhibits the Growth  and Migration in Renal Cell Carcinoma Cells},
JOURNAL = {Oncology Research},
VOLUME = {25},
YEAR = {2017},
NUMBER = {3},
PAGES = {389--395},
URL = {http://www.techscience.com/or/v25n3/56818},
ISSN = {1555-3906},
ABSTRACT = {The pre-mRNA splicing regulator serine–arginine protein kinase 1 (SRPK1), a member of the SR kinase 
family, plays an essential role in cancer development and various pathophysiological processes. However, its 
expression pattern and functions in renal cell carcinoma (RCC) remain unknown. Therefore, the aim of this 
study was to assess the role of SRPK1 in RCC. Our data showed that SRPK1 was significantly upregulated in 
human RCC tissues and cell lines. SRPK1 interference significantly inhibited the proliferation of RCC cells 
and inhibited tumor growth in vivo. In addition, SRPK1 interference also suppressed migration and invasion 
in RCC cells. A mechanistic study showed that SRPK1 interference inhibited the phosphorylation of PI3K and 
Akt in RCC cells. In conclusion, our findings suggest that SRPK1 interference inhibits the growth and invasion 
of RCC cells through suppressing the PI3K/Akt signaling pathway. Thus, SRPK1 might be a therapeutic target 
for the treatment of RCC.},
DOI = {10.3727/096504016X14743324568129}
}